Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Shutdown Plan: Some User Fee Services Would Continue; Routine Inspections Would Not

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency would retain 8,180 staff members, about 55% of its total, mostly because they could be “paid from carryover funding.”

You may also be interested in...



FDA's Government Shutdown Plan Ready, Just In Case

With a little more than a week left for Congress to extend government funding, US FDA and HHS plan for furloughs should no new appropriations be enacted.

A Burning FDA Hiring Freeze Question: What About User Fee-Supported Staff?

Industry worries about user fee programs as US FDA could wait weeks before finding out how President Trump's hiring freeze affects it.

A Burning FDA Hiring Freeze Question: What About User-Fee-Supported Staff?

Industry worries about user fee programs as US FDA could wait weeks before finding out how President Trump's hiring freeze affects it.

Related Content

Topics

UsernamePublicRestriction

Register

LL1126230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel